Immunome Inc

IMNM remains in Stage 2 advancing with established higher highs and higher lows, supported by rising EMAs and healthy volume. The recent pullback into the rising EMA zone offers an attractive entry for continuation participation in the momentum trend. Execution is warranted now, targeting shallow pullbacks into the 9/21 EMA support area. A sustained break and close below the 50-day SMA on heavier volume would invalidate this view.

• ↑FDA acceptance of Varegacestat NDA marks key commercialization milestone
• ↑344 000 inducement shares awarded, strengthening research team
• ↓Negative earnings yield highlights weak profitability prospects